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Introduction {#sec1}
============

Thymic regulatory T (Treg) cells, defined as CD4^+^CD25^+^Foxp3^+^ T cells, are instrumental for the maintenance of tolerance to self-antigens. Treg cells exert their immunomodulatory role by localizing to both lymphoid and non-lymphoid tissue.

A rapid accumulation of Treg cells relative to T effector (Teff) cells---in which more than 30% of the infiltrating lymphocytes are Treg cells---occurs in inflamed tissue during immune regulation ([@bib44]). By contrast, the small proportion of these cells in the peripheral blood (2%--5%) further emphasizes their remarkable migratory ability.

The bioenergetics of Teff and Treg cell function, expansion, and survival has been extensively studied. Teff and Treg cells require distinct metabolic programs to support their survival and differentiation: T helper (Th)1, Th2, and Th17 cells express high surface amounts of glucose transporter Glut1 and are highly glycolytic, whereas Treg cells express low amounts of Glut1 and have high lipid oxidation rates *in vitro* ([@bib28]). The mammalian target of rapamycin (mTOR) plays a key role in cell fate decision by regulating T cell metabolic responses. T cell activation stimulates mTOR to increase glycolysis and diminish lipid oxidation ([@bib49]). In contrast, blockade of glycolysis promotes generation of Treg cells, and this occurs via inhibition of mTOR-mediated induction of the transcription factor hypoxia-inducible factor (HIF1α) ([@bib10], [@bib41]). However, while Treg cells mainly rely upon an oxidative metabolism, some specific functions can be dependent on a selective switch to glycolysis. Their metabolism appears to oscillate from mTOR-dependent and -independent pathways in response to environmental cues ([@bib39]). Toll-like receptor (TLR) signals promote Treg cell proliferation via mTORC1 signaling, glycolysis, and Glut1 upregulation, but these signals also reduce their suppressive ability ([@bib15]).

Despite motility being likely the most energy-consuming cellular activity ([@bib3]), the metabolic demands for T cell migration have been only partly investigated. We have shown that Teff cell migration relies upon the glycolytic pathway ([@bib16]). However, the metabolic program(s) that fuel Treg cell migration remain unknown.

Integrins such as LFA-1 play a key role T cell trafficking; in addition, signals generated by the co-stimulatory or the co-inhibitory receptors CD28 and CTLA-4, respectively, actively participate in the regulation of T cell trafficking. In the lymph nodes, CD28 activation promotes memory T cell egression and migration to target tissue ([@bib19], [@bib29]), while CTLA-4 antagonizes CD28 pro-migratory signals ([@bib29]). Effector Treg cell migration is also regulated by CD28 signals ([@bib30]). Importantly, costimulatory receptors also regulate T cell metabolic reprogramming to enhanced glycolysis ([@bib12], [@bib37]), suggesting that glycolysis and migration might be tightly linked in Treg cells.

By comparing LFA-1- and CD28-mediated pro-migratory signals as a working model, we have investigated the bioenergetics of migrating Treg cells *in vitro* and *in vivo*. We here define a specific pathway of metabolic reprogramming sustaining Treg cell migration both in mice and humans.

Results {#sec2}
=======

Engagement of the Glycolytic Pathway Is Required for Treg Cell Migration {#sec2.1}
------------------------------------------------------------------------

Given that Treg cells display high lipid oxidation, we first tested the hypothesis that *ex vivo* expanded thymic Treg cell migration may require fatty acid oxidation (FAO) by exposing the cells to acetyl-CoA carboxylase (ACC) inhibitor Etomoxir ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). This pre-treatment did not affect Treg cell transendothelial migration (TEM) or chemotaxis *in vitro* ([Figures 1](#fig1){ref-type="fig"}A, 1D, and 1E, respectively, and [S1](#mmc1){ref-type="supplementary-material"}A--S1E) or migration to inflamed peritoneum *in vivo* ([Figures 1](#fig1){ref-type="fig"}F and 1G).Figure 1Glycolysis Fuels Treg Cell Migration(A--E) *Ex vivo* expanded Treg cells pre-treated with the indicated drugs or vehicle for 4 hr were left to migrate through 3 μm-pore transwells layered with IFN-γ-treated syngeneic EC monolayers (A--C) or in response to chemokine CCL22 through bare-filter 5 μm-pore transwells (D and E). Results are expressed as percentage of migrated cells after 24 hr (A--C, n = 4, N = 2) or at the indicated time points (D, n = 3) ± SD. The fold increase in migration was calculated by dividing experimental migration by spontaneous migration measured at 6 hr in two experiments of identical design performed in triplicates ± SD.(F--K) Drug- or vehicle-treated Treg cells labeled with PKH26 were injected i.v. into syngeneic recipients treated with IFN-γ i.p. 48 hr earlier. Cells were harvested from the indicated tissues after 24 hr and analyzed by flow cytometry. Representative dot plots from 3 animals are shown in (F), (H), and (J). The mean absolute number of labeled cells recovered in 4 animals ± SD is shown in (G), (I), and (K) (N = 1).(L and M) Representative histograms from 3 independent experiments of Treg cells stimulated with plastic-bound recombinant (r)ICAM-1 or human IgG Fc fragments (Fc) for 45 min and then re-suspended in medium containing the glucose uptake indicator 6-NBDG for 10 min. The mean MFI ± SD is shown in (M).(N and O) ECAR of ICAM-1- (N) or CCL22-stimulated (O) cells was measured by an extracellular flux analyzer (Seahorse). Ig Fc or medium was used as a control. Recombinant molecules and glucose were added at the time points indicated (±SD n = 5, N = 2).^∗^p \< 0.05, ^∗∗^p \< 0.005. Please see also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We subsequently explored the possibility that, like conventional T cells (Tconv), Treg cells utilize glycolysis for migration, by inhibiting this pathway with the glucose analog 2-deoxyglucose (2-DG). Treg cells exposed to 2-DG migrated inefficiently both *in vitro* ([Figures 1](#fig1){ref-type="fig"}B, 1D, 1E, [S1](#mmc1){ref-type="supplementary-material"}D, and S1E) and *in vivo* ([Figures 1](#fig1){ref-type="fig"}H and 1I). In addition to extensive washing after exposure to the drugs, the inhibition of Treg cell chemotaxis excludes indirect effects of the drugs on the endothelium in these conditions. In contrast, activation of glycolysis using metformin, which stimulates glycolysis via AMP kinase, increased Treg cell motility ([Figures 1](#fig1){ref-type="fig"}C--1E, [S1](#mmc1){ref-type="supplementary-material"}D, and S1E) and trafficking ([Figures 1](#fig1){ref-type="fig"}J and 1K). None of the drugs affected expression of migration-relevant receptors or viability at the doses used ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G). To confirm that the effect of each of these compounds is retained once *in vitro* treated T cells are injected into recipient mice, Treg cells were exposed to the various drugs for 4 hr, extensively washed, and incubated in culture medium alone for a further 16 hr. The effects on drug-treated cell motility were still apparent after the prolonged incubation without the compounds ([Figures S1](#mmc1){ref-type="supplementary-material"}I--S1N).

To confirm the induction of the glycolytic pathway by pro-migratory stimuli, we subsequently tested the effect of engagement of the adhesion molecule integrin LFA-1, a key mediator of T cell migration, on aerobic glycolysis in Treg cells. Immobilized or antibody-ligated recombinant mouse ICAM-1 (rICAM-1), a ligand of LFA-1, was used for this purpose.

First we estimated LFA-1-induced glucose uptake using the glucose analog 6-\[N-(7-nitrobemz-2-oxa-1,3-diazol-4-yl)amino\]-2-deoxyglucose (6-NBDG), which cannot be phosphorylated by hexokinases and accumulates in the cytoplasm in its fluorescent form. Treg cells were stimulated with plastic-bound rICAM-1 or human IgG Fc fragments (control) and 6-NBDG uptake was measured 30 min later by flow cytometry. As shown in [Figures 1](#fig1){ref-type="fig"}L and 1M, LFA-1 stimulation significantly increased 6-NBDG uptake.

Second, we measured the effects of LFA-1 engagement or exposure to the chemokine CCL22 (CCR4 ligand) on the extracellular acidification rate (ECAR), which quantifies proton production as a surrogate for lactate production and thus reflects overall glycolytic flux. ECAR increase upon glucose supply was significantly enhanced following LFA-1 or CCR4 ([Figures 1](#fig1){ref-type="fig"}N and 1O) stimulation. Meanwhile, the oxygen consumption rate (OCR), a measure of mitochondrial respiration, was not affected ([Figures S1](#mmc1){ref-type="supplementary-material"}N and S1O).

CD28 and CTLA-4 Regulate Treg Cell Migration through Modulation of the Glycolytic Pathway {#sec2.2}
-----------------------------------------------------------------------------------------

As triggering of LFA-1 by endothelial ICAM-1 is a frequent event during recirculation---hence difficult to manipulate---to address the metabolic requirement of Treg cell trafficking *in vivo* we subsequently focused on the effects CD28 and CTLA-4 ([Figure S2](#mmc1){ref-type="supplementary-material"}A) costimulatory and coinhibitory signals, which can be delivered *ex vivo* with well-characterized reagents ([Figure S2](#mmc1){ref-type="supplementary-material"}B).

First, we confirmed that antibody activation of CD28 enhances *ex vivo* expanded Treg cell TEM ([Figure S2](#mmc1){ref-type="supplementary-material"}C) and chemotaxis ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E) *in vitro* and migration *in vivo* ([Figure S2](#mmc1){ref-type="supplementary-material"}F), without affecting expression of relevant receptors ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H). Also, we observed that while CTLA-4 triggering alone did not affect cell migration, co-ligation with CD28 abrogated CD28-induced migration ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D).

Second, we measured the impact of CD28 and CTLA-4 signals on the glycolytic pathway in Treg cells. CD28 triggering significantly increased 6-NBDG uptake ([Figures 2](#fig2){ref-type="fig"}A and 2B) and glycolytic flux ([Figure 2](#fig2){ref-type="fig"}C) compared to treatment with an isotype control and secondary antibodies. In contrast, CTLA-4 stimulation did not affect either glucose uptake or ECAR on its own but when co-ligated, CTLA-4 signals prevented CD28-induced glucose uptake and ECAR increase. The oxygen consumption rate (OCR) was not affected by triggering of either costimulatory receptor ([Figures S2](#mmc1){ref-type="supplementary-material"}I and S2J).Figure 2Treg Cell Migration Is Regulated by Co-stimulatory Receptors via Induction of Glycolysis(A and B) Representative histograms from 3 independent experiments of antibody-stimulated Treg cells incubated with 6-NBDG for 10 min prior to analysis. The non-fluorescent glucose analog 2-DG was used as a negative control. The mean MFI ± SD is shown in (B) (N = 3).(C) ECAR of antibody-stimulated Treg cells was measured by fluxometry. Antibodies (Ab) and D-glucose were injected at the indicated time points ± SD.(D--F) ECAR (±SD) was measured in WT or *Ctla4*^*−/−*^ Treg cells either unstimulated (D) or previously stimulated with recombinant CD80 or Fc fragments for 30 min (E and F). D-glucose was injected as indicated by the green line.(G) Migration of rCD80- or Fc-stimulated *Ctla4*^*−/−*^ and WT Treg cells through syngeneic IFN-γ-treated EC monolayers. Results are expressed as mean percentage of migrated cells at 24 hr ± SD n = 3, N = 4.(H) Migration of antibody-stimulated Treg cells re-suspended in either glucose-free or glucose-reconstituted medium through IFN-γ-treated syngeneic EC monolayers, expressed as percentage of migrated cells after 24 hr ± SD (n = 3, N = 4).(K) Antibody-stimulated Treg cells labeled with PKH26 (red) were injected i.p. in C57BL/6 mice given IFN-γ i.p. 48 hr earlier. 6-NBDG (green) was injected i.p. immediately after. Peritoneal membranes were removed 1 hr later, counterstained with DAPI and imaged by wide-field fluorescence microscopy to determine the number of infiltrating cells and 6-NBDG uptake by the infiltrating cells. Representative images from 2 independent experiments are shown in (I). The mean number of cells counted in 10 10× fields from 4 recipients ± SD and the mean total cell fluorescence of 6-NBDG from 10--12 cells from 3 10× fields ± SD are shown in (J) and (K), respectively (n = 4, N = 2).^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.005. Please see also [Figure S2](#mmc1){ref-type="supplementary-material"}.

We further explored the link between costimulatory signals and metabolic regulation of motility by analyzing the metabolic activity and migration of *Ctla4*^*−/−*^ Treg cells. In these experiments we used as stimulator recombinant (r)CD80, a ligand shared by CD28 and CTLA-4. Compared to WT Treg cells, *Ctla4*^*−/−*^ cells displayed a prolonged increase of ECAR in response to glucose ([Figure 2](#fig2){ref-type="fig"}D)---even taking into account a higher acidification baseline. As expected, the ECAR of WT Treg cells activated with recombinant CD80 remained unchanged, due to simultaneous CD28 and CTLA-4 engagement ([Figure 2](#fig2){ref-type="fig"}E), while *Ctla4*^*−/−*^ cells further increased their glycolytic response to glucose addition ([Figure 2](#fig2){ref-type="fig"}F). Despite the fact that *Ctla4*^*−/−*^ cell OCR was spontaneously higher than that of their WT counterparts, it was not affected by either CD28 or CTLA-4 signals ([Figure S2](#mmc1){ref-type="supplementary-material"}K).

In parallel, we tested TEM by rCD80-stimulated *Ctla4*^*−/−*^ Treg cells through IFN-γ-activated syngeneic EC. As shown in [Figure 2](#fig2){ref-type="fig"}G, *Ctla4*^*−/−*^ Treg cell stimulated with recombinant CD80 displayed enhanced migration through EC while WT Treg cells did not respond to such stimulation, supporting the conclusion that CTLA-4 signals inhibit CD28-induced glycolysis and migration.

To investigate whether control of Treg cell migration by CD28 and CTLA-4 occurs via modulation of glycolysis, we analyzed the effect of CD28 and/or CTLA-4 stimulation during TEM in glucose-depleted medium. As shown in [Figure 2](#fig2){ref-type="fig"}H, glucose depletion prevented the increase in motility induced by CD28 signals. The results were not influenced by cell distress associated with glucose deprivation as baseline migration remained similar in both glucose-sufficient and -deficient conditions.

*In vivo*, the CD28-glycolysis-migration axis was analyzed by monitoring 6-NBDG uptake by CD28-stimulated migrating Treg cells. To this aim, we used a tissue infiltration model in which the ability of Treg cells injected in the peritoneal cavity to infiltrate the peritoneal membrane is quantified ([@bib29]). This model was chosen because 6-NBDG fluorescence is rapidly lost with time, making it technically impossible to track T cells transferred intravenously long-term. Treg cells were labeled with PKH26 (red fluorescence) and then underwent CD28 ligation with or without CTLA-4 triggering, or received isotype-matched and secondary antibodies as a control prior to i.p. injection in syngeneic mice treated with IFN-γ 48 hr earlier. 6-NBDG (green fluorescence) was injected i.p. immediately after the cells, thus allowing parallel evaluation of tissue infiltration and glucose uptake by labeled Treg cell *in vivo*. As shown in [Figures 2](#fig2){ref-type="fig"}I--2K, CD28 activation substantially increased the number of cells infiltrating the peritoneum and displaying 6-NBDG uptake (yellow fluorescence), indicating that Treg cell migration directly correlates with glucose uptake *in vivo*. Both these effects were prevented by CTLA-4 co-ligation.

Enhancement of Glycolysis and Migration Requires PI3K-Akt Activation but Is Independent of mTORC1 {#sec2.3}
-------------------------------------------------------------------------------------------------

CD28 stimulation induces glucose uptake and glycolysis via activation of the PI3K-Akt signaling pathway ([@bib12], [@bib18]). PI3K activation by CD28 is instrumental for the transduction of pro-migratory signals, without affecting expression of migratory receptors, in conventional T (Tconv) cells ([@bib20]), and inefficient migration of T cells to the inflammatory site is a feature of *Cd80*^*−/−*^*Cd86*^*−/−*^ mice ([@bib6]). To investigate the role of CD28-induced activation of the PI3K pathway on Treg cell metabolism and migration, we isolated Treg cells from *Cd28*^Y170F^ genetically targeted mice, which carry a mutation in the cytoplasmic tail of CD28 that selectively prevents recruitment of PI3K ([@bib36]). *Cd28*^Y170F^ Treg cells display normal development ([@bib42]) and expression of migration-relevant and other receptors ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

First, we compared the mobilization and recirculation of WT and *Cd28*^Y170F^ Treg cells following i.p. injection of Zymosan. Activation of innate but not adaptive immunity by this method has been shown to induce accumulation of Treg cells in the peritoneal cavity with a peak 72 hr after injection ([@bib32]). As shown in [Figures 3](#fig3){ref-type="fig"}A and 3B, WT and *Cd28*^Y170F^ Treg cells---identified as shown in [Figure S3](#mmc1){ref-type="supplementary-material"}B---increased in the peripheral blood to similar amounts by 72 hr after Zymosan injection. However, *Cd28*^Y170F^ Treg cells did not efficiently migrate to the peritoneal cavity and lymph nodes, indicative of inadequate extravasation from the bloodstream. CD28 is likely to be engaged during interactions with LPS-activated dendritic cells. The ratio of WT Treg cells in LN and blood and in blood and peritoneum decreased over time, indicating a LN-to-blood-to-peritoneum recirculation ([Figures 3](#fig3){ref-type="fig"}C and 3D). In contrast, the distribution of *Cd28*^Y170F^ Treg cells remained stable, confirming their impaired recirculation and additionally suggesting that the increase of these cells in the blood is likely due to passive mobilization from the spleen. Thus, CD28 instructs Treg cell recirculation in response to activation of innate immunity.Figure 3CD28-Induced Migration and Metabolic Reprogramming Require PI3K but Not mTORC-1 ActivationWT and *Cd28*^Y170F^ mice received an i.p. injection of Zymosan. Samples were collected either before or 72 hr after the injection. The presence of Treg cells in the indicated tissues was measured by flow cytometry.(A) Representative dot plots from 2 independent experiments.(B) The mean percentage of cells measured in two experiments of identical design ± SD.(C and D) Ratio of cells retrieved in the indicated tissues over time ± SD (n = 3).(E) ECAR (±SD) of antibody-stimulated *Cd28*^Y170F^ and WT Treg cells was compared using fluxometry. n = 4, N = 2.(F) Migration of antibody-stimulated *Cd28*^Y170F^ and WT Treg cells through IFN-γ-treated EC monolayers. Results are expressed as mean percentage of migrated cells after 24 hr ± SD. N = 4.(G--J) Equal numbers of antibody-stimulated PKH26-labeled WT or *Cd28*^Y170F^ Treg cells were injected i.v. into syngeneic mice treated with IFN-γ i.p. 48 hr earlier. Cells were harvested from the indicated tissues 24 hr later, counter-stained for Foxp3, and analyzed by flow cytometry. Representative dot plots of 2 independent experiments are shown in (G) and (I). The bar graphs in (H) and (J) indicate mean absolute numbers of labeled cells (n = 4, N = 2) ± SD.^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.005. Please see also [Figure S3](#mmc1){ref-type="supplementary-material"}.

We subsequently compared the ECAR of CD28-stimulated purified *Cd28*^Y170F^ and WT Treg cells. After glucose addition, the ECAR increase in CD28-stimulated *Cd28*^Y170F^ cells was significantly dampened ([Figure 3](#fig3){ref-type="fig"}E), suggesting that PI3K recruitment by CD28 signals is required to efficiently induce glycolysis.

We then analyzed the migratory response to CD28 triggering by Treg cells isolated and expanded from both WT and *Cd28*^Y170F^ mice. As shown in [Figures 3](#fig3){ref-type="fig"}F--3J, CD28 stimulation failed to enhance migration of *Cd28*^Y170F^ Treg cells *in vitro* ([Figure 3](#fig3){ref-type="fig"}F) and *in vivo* ([Figures 3](#fig3){ref-type="fig"}G--3J), confirming the pivotal role of CD28-mediated recruitment of PI3K in enhancing Treg cell migration.

In most T lymphocytes, mTOR kinase couples upstream PI3K and Akt to glucose uptake and glycolysis ([@bib7], [@bib38]). In Treg cells, CD28 signals induced phosphorylation of the mTORC1 target ribosomal protein S6 ([Figure S3](#mmc1){ref-type="supplementary-material"}C), an event that was prevented by CTLA-4 co-ligation. Rapamicyn treatment prevented Treg cells entering the cell cycle---as measured by the expression of the proliferating cell nuclear antigen (PCNA)---in response to immature cognate DCs and rIL-2 ([Figure S3](#mmc1){ref-type="supplementary-material"}D), and CD28-induced phosphorylation of ribosomal protein S6 ([Figure S3](#mmc1){ref-type="supplementary-material"}E). However, rapamycin did not affect CD28-induced migration *in vitro* ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G) or *in vivo* ([Figures S3](#mmc1){ref-type="supplementary-material"}H--S3K), suggesting that CD28 promotes Treg cell migration via mediators downstream of PI3K other than mTORC1.

Pro-migratory Stimuli Induce Metabolic Reprogramming {#sec2.4}
----------------------------------------------------

We have previously shown that in Tconv cells, activation of glycolysis during migration occurs via transcriptional and post-transcriptional regulation of the enzyme Hexokinase (HK)I ([@bib16]). We therefore analyzed the expression of a number of glycolytic enzymes by expanded Treg cells 4 hr after CD28 and CTLA-4 stimulation. CD28 stimulation led to a modest increase in HKI, Enolase, and Aldolase expression by Treg cells ([Figures 4](#fig4){ref-type="fig"}A and 4B). The most substantial increase was observed in the expression of the HK isoenzyme glucokinase (HKIV or GCK), a rate-limiting enzyme key to hepatocyte and pancreatic beta cell function, whose expression by T cells has not been previously reported. Concomitant CTLA-4 triggering inhibited CD28-induced enzyme expression.Figure 4Pro-migratory Stimuli Induce Metabolic Reprogramming of Treg Cells(A and B) Expression of the indicated enzymes in Treg cells was measured 4 hr after antibody stimulation by western blotting. In (B) the mean relative expression measured by densitometric analysis in 3 independent experiments ± SD is shown.(C) Expression of the indicated enzymes by CD28- or LFA-1-stimulated Treg cells measured by western blotting at the indicated time points.(D--G) Relative mRNA expression of GCK (D) and GCKR (E) and cellular protein expression (F and G) by antibody-stimulated Treg cells was measured by RT-PCR and confocal microscopy, respectively. In (G) the mean MFI ± SEM measured using ImageJ software is shown. N = 3. Scale bar 20 μm.(H) AZD1656 (GCK activator, 1 μM) and vehicle-treated Treg cells (2 hr in insulin-free medium) were labeled with different intravital fluorescent dyes, and co-injected into syngeneic recipients that had received IFN-γ i.p. 48 hr earlier. Cells were recovered from the peritoneum or spleen after 24 hr and analyzed by flow cytometry. Representative dot plots from 2 independent experiments are shown. The bar graphs indicate mean absolute number of labeled cells retrieved ± SD (n = 4, N = 2).(I and J) expression of PCNA by Treg cells stimulated with allogeneic DCs following treatment with either AZD1656 (I) or Clotrimazole (CLT, 1 μM, 2 hours, J) or vehicle alone was measured by flow cytometry. NS, non-stimulated control cells. Representative histograms from 3 independent experiments are shown. (n = 3, N = 3).(K) ECAR of Treg cells activated with recombinant ICAM-1 or Fc control. CLT or vehicle as well as other glycolysis-affecting drugs were added as indicated.(L) CLT- or vehicle-treated Treg cells underwent CD28 or isotype-matched antibody stimulation, labeled with different intravital fluorescent dyes, and injected i.v. in syngeneic recipients that had received IFN-γ i.p. 48 hr earlier. Cells were recovered from the peritoneum (P) or spleen (S) after 24 hr and analyzed by flow cytometry. Representative dot plots from 2 independent experiments are shown. The column graphs indicate mean absolute number of labeled cells retrieved ± SD (n = 3, N = 2).^∗^p \< 0.05 ^∗∗∗^p \< 0.005; ^∗∗∗∗^p \< 0.001. Please see also [Figure S4](#mmc1){ref-type="supplementary-material"}.

We extended our analysis also to HKII and observed that, like that of GCK, a substantially enhanced expression of this enzyme occurred as early as 5 min after stimulation not only by CD28 signals, but also following LFA-1 triggering by recombinant ICAM-1 ([Figures 4](#fig4){ref-type="fig"}C, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B), suggesting that both stimuli enhance enzyme expression also by post-transcriptional mechanisms.

We then measured transcription of the GCK, HKI, and HKII genes, which was indeed increased by LFA-1 or CD28 stimulation ([Figures 4](#fig4){ref-type="fig"}D, [S4](#mmc1){ref-type="supplementary-material"}C, and S4D, respectively). As expected, enzyme induction by CD28 was prevented by CTLA-4 triggering. In this set of experiments, transcription of the GCK regulatory protein (GCKR) gene ([Figure 4](#fig4){ref-type="fig"}E), a post-transcriptional regulator which blocks free cytoplasmic GCK ([@bib11]), was also analyzed. Confocal analysis of expression and co-localization of GCK and GCKR following CD28 and LFA-1 activation confirmed that both CD28 and LFA1 stimuli decrease GCKR expression, concomitant to a substantial increase of GCK availability ([Figures 4](#fig4){ref-type="fig"}F and 4G).

To address the relative contribution of HKII and GCK activity to their motility, Treg cells were treated with either the GCK activator AZD1656 ([@bib47]) or with the HKII-selective inhibitor Clotrimazole (CLT), which inhibits the glycolytic flux and respiration in CD3 plus CD28-stimulated Tconv cells ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F; [@bib45]). GCK activation significantly enhanced Treg cell migration to the inflamed tissue ([Figure 4](#fig4){ref-type="fig"}H) but did not affect division ([Figure 4](#fig4){ref-type="fig"}I). Conversely, CLT was effective at inhibiting PCNA upregulation by Treg cells ([Figure 4](#fig4){ref-type="fig"}J) in response to allogeneic DCs but did not affect rICAM-1-mediated induction of glycolysis ([Figure 4](#fig4){ref-type="fig"}K) or migration to inflamed peritoneum *in vivo* ([Figure 4](#fig4){ref-type="fig"}L), implying that HKII is redundant for Treg cell migration.

mTORC2-Dependent Induction of GCK Expression Is Required for Treg Cell Migration {#sec2.5}
--------------------------------------------------------------------------------

The above observations implicate GCK as a key enzyme induced by both CD28- and LFA-1-mediated signals in migrating Treg cells. GCK expression in the liver is regulated by the relatively rapamycin-insensitive mTORC2 ([@bib17]).

Based on this evidence and the observation that CD28-induced Treg cell trafficking is PI3K dependent but rapamycin insensitive ([Figures 3](#fig3){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}), we examined the contribution of mTORC2 signaling to Treg cell metabolism and migration. First, we confirmed that CD28 triggering led to mTORC2-dependent AKT phosphorylation at the serine residue 473 ([Figure 5](#fig5){ref-type="fig"}A). Subsequently, expression of Rictor, an obligatory component of mTORC2, was prevented in expanded Treg cells by lentivirus-delivered, specific shRNAs ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). For comparison we also silenced GCK expression. As a control, cells were transduced with an empty vector (PLKO.1). Gene silencing did not affect cell survival ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). Rictor-depleted Treg cells became unable to upregulate GCK protein expression following CD28 and LFA-1 stimulation ([Figure 5](#fig5){ref-type="fig"}B), suggesting that this event was mTORC2 dependent. Confocal analysis of Rictor-deficient cells confirmed their failure to upregulate GCK expression in response to the pro-migratory signals compared to mock-transduced cells ([Figures 5](#fig5){ref-type="fig"}C and 5D). Furthermore, Treg cells lacking mTORC2 activity did not downregulate GCKR expression ([Figure 5](#fig5){ref-type="fig"}E). The ability of Rictor- and GCK-shRNA silenced Treg cells to enhance the glycolytic flux upon CD28 or LFA-1 stimulation was also significantly impaired compared to mock-transduced cells ([Figure 5](#fig5){ref-type="fig"}F). A glycolysis stress test showed that, although they were unable to increase the glycolytic flux in response to CD28 and LFA-1 signals, both Rictor- and GCK-deficient Treg cells maintained a basal and maximal glycolytic response ([Figures 5](#fig5){ref-type="fig"}G and 5H), while their glycolytic reserve was significantly impaired ([Figure 5](#fig5){ref-type="fig"}I).Figure 5mTORC2 Controls Metabolic Reprogramming Induced by Pro-migratory Stimuli(A) Phosphorylation of AKT at Thr~308~ and Ser~473~ in Treg cells activated with CD28- or IsC-antibody ligation was measured by immunoblotting.(B) Treg cells were virally transfected with Rictor-specific or GCK-specific or non-sense (PLKO.1) sh-RNAs, as described in [STAR Methods](#sec5){ref-type="sec"}. Expression of GCK was measured by immunoblotting 24 hr later.(C--E) Expression of GCK and GCKR by control or Rictor-deficient Treg cells following CD28 or LFA-1 activation for 45 min. Bar graphs (D and E) show the mean protein expression (Total cell fluorescence) measured in 3 independent experiments by ImageJ software ± SD. Scale bar, 40 μm.(F--I) ECAR of CD28- or LFA-1-stimulated Rictor- and GCK-deficient and control T cells was measured with an extracellular flux analyzer. A glycolysis stress assay was performed by adding the indicated compounds at the time points indicated by the green lines. The basal and maximal glycolysis and the glycolytic reserve are shown in (G), (H), and (I), respectively (±SEM). N = 2.^∗^p \< 0.05 ^∗∗∗^p \< 0.005; ^∗∗∗∗^p \< 0.001. Please see also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Despite these metabolic alterations, the suppressive and proliferative capacity of Rictor- and GCK-deficient Treg cells were similar to those of their mock-transduced counterpart ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C), indicating that this pathway was not required for these functions.

To assess whether the metabolic impairment resulted in alteration of migratory responses, differentially labeled cells transduced with Rictor- or GCK-specific or control shRNAs underwent CD28 or IsC antibody ligation prior to co-injection in syngeneic recipients, which had received a i.p. injection of IFN-γ 48 hr earlier. Their migration to the peritoneal cavity, spleen, and LN was compared 16 hr later. Both Rictor- and GCK-depleted Treg cell migration to the inflammatory site was severely impaired compared to that by mock-transduced cells and was not enhanced by CD28 activation ([Figures 6](#fig6){ref-type="fig"}A and 6B). In addition, although similar numbers of cells were injected, significantly lower numbers of GCK-deficient Treg cells were retrieved in the spleen---where early migration does not require active mechanisms---compared with Rictor-deficient or mock-transduced cells ([Figures 6](#fig6){ref-type="fig"}C and 6D). We hypothesized that the severe impairment of GCK-deficient Treg cell cytoskeleton might render them unable to squeeze through the pulmonary capillaries and leave the lungs following injection in the venous blood. Indeed, the ratio of GCK-deficient cells retrieved in the lung and the spleen was significantly increased compared to that of control cells independently of CD28 activation ([Figure 6](#fig6){ref-type="fig"}E). In addition, although inefficiently compared to mock-transduced cells, shGCK Treg cells were still capable of migrating through pores with a 5 μm diameter in chemotaxis assays, but failed to migrate through 3 μm pores ([Figures 6](#fig6){ref-type="fig"}F and 6G), suggesting a severe impairment of cytoskeletal function as a consequence of loss of GCK activity.Figure 6Rictor-Deficient Treg Cells Display Impaired Motility(A--E) CD28-stimulated or IsC-treated PLKO.1, Rictor- or GCK-deficient Treg cells were labeled with PKH26 and co-injected i.v. with identical numbers of IsC-treated CFSE-labeled cells in syngeneic recipients treated with IFN-γ 48 hr earlier. The presence of differently labeled cells in the indicated organs was assessed by flow cytometry 24 hr later. Representative dot plots from 3 independent experiments are shown on top in (A), (B), and (C). The bar graphs in (A), (B), and (D) indicate mean absolute number of labeled Treg cells recovered in the indicated tissues from 4 different recipients ± SD (N = 3). The bar graph in (E) shows the ratio of Treg cells recovered in the lung and the spleen (n = 4) ± SD.(F and K) Control and ShGCK Treg cell migration through 5 or 3 μm pore bare-filter transwells in response to CCL22 (F) or CXCL10 (K). Results are expressed as percentage of migrated cells at the indicated time points ± SD (n = 3).(H--J) BALB/c-derived skin was grafted onto C57BL/6 recipients who had received mock-transduced, Rictor- or GCK-depleted Treg cells or no cells 24 hr earlier. Graft rejection was monitored daily (H). Some grafts were removed 5 days post-grafting and the presence of fluorescently labeled Treg cells in the indicated tissue was assessed by widefield fluorescence microscopy. Representative images of grafts and spleens from 2 independent experiments are shown in (I). The bar graphs (J) indicate the mean number of labeled cells detected in at least 10 10× tissue images from each animal ± SD (n = 8).^∗^p \< 0.05 ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.005. Please see also [Figure S6](#mmc1){ref-type="supplementary-material"}.

In this context, we observed that pro-migratory activity of CD28 signals was accompanied by intense actin remodeling, which was prevented by CTLA-4 signals ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E). Glycolytic enzymes including GCK interact with actin ([@bib8], [@bib31]) to act as a glycolytic ATP feeder for the ATP-hydrolyzing sodium pump (Na,K-ATPase), thus generating energy required for cytoskeletal rearrangements ([@bib21]). We therefore assessed GCK and Na,K-ATPase localization on the actin cytoskeleton in CD28- and LFA-1-stimulated Treg cells. First, we observed that GCK became associated with actin following CD28 stimulation ([Figure S6](#mmc1){ref-type="supplementary-material"}F). Further, unstimulated cells displayed reduced F-actin and GCK expression, which appeared associated with the cytoskeleton ([Figures S6](#mmc1){ref-type="supplementary-material"}G--S6I). Similarly, ATPase expression was low and only partially co-localized with GCK ([Figures S6](#mmc1){ref-type="supplementary-material"}G, S6H, and S6J). Stimulation of CD28 or ICAM led to intense F-actin formation and upregulation of associated GCK and increased expression of the Na,K-ATPase, which also associated with GCK ([Figures S6](#mmc1){ref-type="supplementary-material"}G--S6I). As expected, since shRictor-silenced Treg cells produce less GCK, the amount of co-localization with F-actin was also lower.

To further confirm the selective impact of Rictor and GCK deficiency on Treg cell motility, we finally compared the ability of adoptively transferred (10^7^/mouse) control, Rictor-deficient, or GCK-deficient cells to delay rejection of fully allogeneic skin grafts. As expected, Rictor- and GCK-depleted Treg cells failed to prolong graft survival ([Figure 6](#fig6){ref-type="fig"}H) as they did not localize in the graft ([Figures 6](#fig6){ref-type="fig"}I and 6J) compared to mock-transduced cells. In line with previous results, fewer GCK-deficient cells were found also in the spleen.

Human Treg Cells from Homozygous Carriers of a Loss-of-Function Polymorphism in the GCKR Gene Display Enhanced Motility {#sec2.6}
-----------------------------------------------------------------------------------------------------------------------

To test the physiological relevance of this pathway in the human system, we analyzed the number and functional behavior of circulating Treg cells (defined as CD25^hi^CD127^lo^) from carriers of a loss-of-function polymorphism in the GCKR gene (C to T, P446L). P446L-GCKR has reduced inhibitory activity toward GCK and has been associated with decreased fasting plasma glucose and enhanced triglyceride synthesis (these parameters measured in our study population are shown in [Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B) via increased GCK activity in the liver of homozygous carriers ([@bib2]).

The number of circulating Treg cells was decreased in carriers of the rare allele 446L of GCKR gene compared to carriers of the WT allele ([Figures 7](#fig7){ref-type="fig"}A, 7B, [S7](#mmc1){ref-type="supplementary-material"}A, and S7B) while other CD4^+^ T cell populations were unaffected ([Figures 7](#fig7){ref-type="fig"}C--7E). Importantly, 446L-GCKR Treg cells displayed increased chemokine-induced motility compared to WT-GCKR Treg cells, while Tconv cell migration was unaffected ([Figures 7](#fig7){ref-type="fig"}F and 7G). The suppressive ability and phenotype of P446L-GCKR Treg cells did not significantly differ from that of WT-GCKR Treg cells ([Figures S7](#mmc1){ref-type="supplementary-material"}C--S7H), including expression of CCR7 ([Figures 7](#fig7){ref-type="fig"}H and 7I), the receptor for the chemokines used in the migration assays. In addition, chemokine-induced molecular events upstream of GCK activation, including glucose uptake ([Figures S7](#mmc1){ref-type="supplementary-material"}I--S7L) and AKT phosphorylation at serine 473 ([Figures S7](#mmc1){ref-type="supplementary-material"}M--S7P), were comparable in 446L- and 446P (WT)-GCKR Treg and Tconv cells, in further support of a key role of increased GCK availability in enhanced 446L-GCKR Treg cell motility.Figure 7Treg Cells Bearing a Loss-of-Function GCKR Allele Display Enhanced Motility(A) Cell number/mL of Treg cells (CD4^+^CD25^hi^CD127^lo^) in carriers of the allele P446L compared to individuals carrying the WT allele (P446).(B) Dot plots representative of 25 individuals analyzed.(C--E) CD4^+^ lymphocyte subpopulations, defined as naive (CD45RA^+^), central memory (CD45RO^+^CD62L^+^CCR7^+^), and effector memory (CD45RO^+^CD62L^−^CCR7^−^) in the two study populations.(F and G) Migratory responses of Treg (F) and Tconv (G) cells from eight P446L-GCKR carriers or WT-GCKR individuals to the chemokines CCL19 and CCL21 were measured by bare-filter 5 μm diameter transwells.(H and I) The percentage of T cells expressing CCR7, receptor for the chemokines CCL19 and CCL 21 used in the migration assays, from P446L-GCKR carriers (n = 8) and WT-GCKR (n = 8) subjects are shown.^∗^p \< 0.05. Please see also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Collectively these observations suggest that GCK contributes to human Treg cell migration.

Discussion {#sec3}
==========

In this study we have investigated the metabolic pathways that sustain migration of thymic Treg cells and how these pathways become engaged by pro-migratory signals.

Our data indicate that migratory stimuli induce metabolic reprogramming of Treg cells toward aerobic glycolysis. However, while induction of the glycolytic pathway in dividing Treg lymphocytes relies upon mTORC1 activity ([@bib15], [@bib39]), activation of glucose metabolism induced by pro-migratory stimuli occurs via mTORC2.

The molecular mechanism for the selective engagement of mTORC2 for the induction of motility-associated glycolysis in Treg cells remains unclear. Physiologically, Treg cells display high activity of rapamycin-sensitive mTOR phosphorylation, which is transiently inhibited by environmental stimuli to allow their proliferation *in vivo* ([@bib39]). A simplistic explanation is that constitutively high mTORC1 activation might limit its availability for additional signals. Thus, glycolysis-activating stimuli in non-proliferating Treg cells may be redirected to the mTORC2 pathway.

Consistent with this hypothesis, mTORC2 regulates the glycolytic flux by fully activating AKT and controlling c-Myc expression which in turn regulate the transcription of genes that control glucose transport and glycolysis, including GLUT1 and HKII ([@bib27]). Finally, mTORC2 is known to mediate cytoskeleton reorganization ([@bib9]) and substantial evidence suggests that its activation requires PI3K activity ([@bib5], [@bib14]), but its ability to promote cell migration via modulation of metabolic pathways has not previously been described.

The dichotomy between regulation of glycolysis during Treg cell proliferation and migration is also reflected in the enzymatic machinery engaged for these cellular responses. Metabolic reprogramming following antigen activation of conventional T cell involves a substantial increase of hexokinase activity, which is dependent on a transcriptional switch in HK isozyme expression from HKI to HKII, which has higher affinity for glucose ([@bib4], [@bib26], [@bib46]). In addition---and as a likely consequence of mTORC2 activation---pro-migratory signals substantially enhance GCK expression. In line with the non-redundant role of mTORC2 in the metabolic regulation of motility, GKC has been shown to be one of the main targets downstream of mTORC2-mediated signaling in the liver ([@bib17]).

We have also provided evidence that this pathway might be operational in the human immune system. The number of circulating Treg cells was decreased in carriers of a GCKR loss-of-function variant and mutant Treg cells display enhanced motility, suggesting increased localization in tissues. Importantly, migration of Tconv cells is not affected by loss of GCKR inhibition and increased GCK activity. The impact of enhanced Treg cell trafficking on immune responses in these individuals will require further investigation.

The physiological significance of preferential utilization of GCK by migrating Treg cells remains to be defined by the use of mice with T cell-specific GCK deficiency. Unlike other hexokinases, GCK has a much lower affinity for glucose, which is within the physiological plasma glucose range (S0.5 ≈7 mM) and is less susceptible to inhibition by the glycolysis metabolite glucose 6-phosphate ([@bib22]). The use of GCK by Treg cells might explain the previous report of a delayed polarization rate of Treg cells, compared to Tconv cells, in response to CD28 stimulation ([@bib30]). CD28-stimulated Treg cells undergo early and late waves of migration, which might reflect the posttranscriptional and transcriptional increase in GCK expression, which we observed. GCK---which is not inhibited by glycolysis metabolites---might also maintain the glycolytic flux and survival in chronic inflammatory sites rich of inhibitory glycolysis metabolites, giving Treg cells an advantage over Tconv cells. In such environments, Tconv cells tend to become hyporesponsive and lose their function as a consequence, for example, of exposure to lactate ([@bib16]). Alternatively, or in addition, dependency on low-affinity GCK might promote retention of Treg cells in glucose-depleted tissues such as tumors.

During immune responses, the ability of CD28 and CTLA-4 to function as a metabolic switch might at least in part explain their opposing effects on T cell division and function. For example, transient CTLA-4 expression following activation might serve to shut down glycolysis, thus supporting reprogramming of long-lived memory CD8^+^ T cells to FAO ([@bib35]), thus promoting the contraction phase of T cell responses and maintaining homeostasis by favoring the induction of anergy ([@bib51]).

While the functional effects of CTLA-4 in the regulation of effector immunity are well established, the contribution of CTLA-4 to Treg cell function is not completely understood. CTLA-4-deficient mice display normal numbers of Treg lymphocytes, which however appear to be defective in their suppressive function *in vivo* ([@bib50]) but not *in vitro* ([@bib43]). Our observations suggest that, by antagonizing CD28-induced migratory signals, CTLA-4 might be required for tissue retention rather than for Treg cell suppressive activity.

Impaired migration of *Cd28*^Y170F^ Treg cells in response to activation of innate immunity also indicates that CD28 signals instruct their mobilization and redistribution from lymphoid tissue -- where CD28 engagement is likely to take place during interaction with activated DCs - to the blood stream. CD28-induced pro-migratory signals might dominate in the absence of cognate interactions thus supporting Treg cell recirculation. In contrast, transient upregulation of CTLA-4 by antigen-activation may reduce their motility leading to retention within tissues.

In summary, this study defines a pathway for the metabolic regulation of motility and migration induced in Treg cells by pro-migratory stimuli. The apparent selectivity of this pathway in the regulation of motility of both murine and human Treg cells suggest that it might be possible to selectively manipulate trafficking of distinct lymphocyte subsets by targeting different glycolytic enzymes. Further, as the signaling mediators involved in the metabolic reprogramming of proliferating Treg cells are distinct from those regulating motility, selective targeting of these enzymes might allow the modulation of distinct functions in therapeutic settings.
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REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse Anti-CD3-PECY7Biolegend100220; RRID: [AB_1732057](nif-antibody:AB_1732057){#intref0010}Mouse Anti-CD4-PEeBioscience12-0042-82; RRID: [AB_465510](nif-antibody:AB_465510){#intref0015}Mouse Anti-Foxp3-APCeBioscience77-5775-40; RRID: [AB_4699981](nif-antibody:AB_4699981){#intref0020}Mouse Anti-CD8-APCeBioscience11-0081-82; RRID: [AB_464915](nif-antibody:AB_464915){#intref0025}Mouse Anti-CD11a-PE-FITCeBioscience11-0111-81; RRID: [AB_464930](nif-antibody:AB_464930){#intref0030}Mouse Anti-CD11c-AF647Biolegend117312; RRID: [AB_389328](nif-antibody:AB_389328){#intref0035}Mouse Anti-CD14-PEeBioscience12-0141-82; RRID: [AB_465563](nif-antibody:AB_465563){#intref0040}Mouse Anti-CD25-PECY7eBioscience12-0251-81; RRID: [AB_465606](nif-antibody:AB_465606){#intref0045}Mouse Anti-CD28-PEeBioscience12-0281-82; RRID: [AB_465621](nif-antibody:AB_465621){#intref0050}Phospho-Akt1 (Ser473)- APCeBioscienceCat \# 17-9715-41; RRID: [AB_2573309](nif-antibody:AB_2573309){#intref0055}Mouse Anti-CD29-APC/CY7Biolegend102226; RRID: [AB_2128076](nif-antibody:AB_2128076){#intref0060}Mouse Anti-CD31-PEeBioscience12-0311-81; RRID: [AB_465631](nif-antibody:AB_465631){#intref0065}Mouse Anti-CD40-PE-FITCBiolegend124607; RRID: [AB_1134090](nif-antibody:AB_1134090){#intref0070}Mouse Anti-CD49d-PEBiolegend103705; RRID: [AB_313046](nif-antibody:AB_313046){#intref0075}Mouse Anti-CD54-PE-FITCBiolegend116105; RRID: [AB_313696](nif-antibody:AB_313696){#intref0080}Mouse Anti-Glut1-PENovusbioNB110-39113PEMouse Anti-CD62L-FITCBiolegend104405; RRID: [AB_313092](nif-antibody:AB_313092){#intref0085}Mouse Anti- CCR4-APCBiolegend131211; RRID: [AB_1279135](nif-antibody:AB_1279135){#intref0090}Mouse Anti-CCR7-APCBiolegend120107; RRID: [AB_389233](nif-antibody:AB_389233){#intref0095}Anti- LPAM-1-APCBiolegend,120607; RRID: [AB_10719833](nif-antibody:AB_10719833){#intref0100}anti-hexokinase-1- C35C4Cell signalingCat.\# 2024anti-CPT1A-D3B3Cell signalingCat.\# 12252anti-enolase-1Cell signalingCat.\# 3810; RRID: [AB_2246524](nif-antibody:AB_2246524){#intref0105}anti-aldolase ACell signalingCat.\# 3188; RRID: [AB_2226674](nif-antibody:AB_2226674){#intref0110}p-S6 (Ser240 and Ser244)Cell signalingCat.\# 2215; RRID: [AB_331683](nif-antibody:AB_331683){#intref0115}anti-S6-5G10Cell signalingCat.\# 2217; RRID: [AB_331355](nif-antibody:AB_331355){#intref0120}Phospho-Akt (Ser473) AntibodyCell signaling\#9271; RRID: [AB_329825](nif-antibody:AB_329825){#intref0125}Akt (pan) (C67E7) Rabbit mAbCell signaling\#4691; RRID: [AB_915783](nif-antibody:AB_915783){#intref0130}anti-GCK -H88Santa Cruz BiotechnologyCat.\# SC7908; RRID: [AB_2107620](nif-antibody:AB_2107620){#intref0135}anti-actin-I19Santa Cruz BiotechnologyCat.\# SC1616; RRID: [AB_630836](nif-antibody:AB_630836){#intref0140}anti-Erk1/2 (H72)Santa Cruz BiotechnologyCat.\# SC292838; RRID: [AB_2650548](nif-antibody:AB_2650548){#intref0145}rat anti-mouse CD8 depletion antibody, clone 53-6.7eBioscience14-0081-82; RRID: [AB_467087](nif-antibody:AB_467087){#intref0150}anti-mouse CD3eBiosciencesCat\# 16-0032-85; RRID: [AB_468852](nif-antibody:AB_468852){#intref0155}anti-mouse CD28eBiosciencesCat\# 16-0281-86; RRID: [AB_468923](nif-antibody:AB_468923){#intref0160}hamster anti-mouse CD28 (clone: 37.52),Bio-RadCat\# MCA1363; RRID: [AB_321560](nif-antibody:AB_321560){#intref0165}goat anti-hamster immunoglobulin (Ig)Bio-RadCat\# STAR104; RRID: [AB_323008](nif-antibody:AB_323008){#intref0170}anti-mouse CTLA-4 (clone: UC10-4F10-11)Becton DickinsonCat\# 553718hamster IgG isotype controlBio-RadCat\# MCA2356; RRID: [AB_567313](nif-antibody:AB_567313){#intref0175}Human IgG Fc fragmentMerck MilliporeAG714; RRID: [AB_97863](nif-antibody:AB_97863){#intref0180}DAPI (4',6-diamidino-2-phenylindole)LifeTechnologiesCat\# D1306; RRID: [AB_2629482](nif-antibody:AB_2629482){#intref0185}alpha 1 Na,K-ATPase antibody \[M8-PI-A3\]Abcamab2872; RRID: [AB_2061140](nif-antibody:AB_2061140){#intref0190}Rabbit Anti-mouse RictorAbcamab70374; RRID: [AB_2253794](nif-antibody:AB_2253794){#intref0195}Anti-GlucokinaseAbcamab88056; RRID: [AB_10673863](nif-antibody:AB_10673863){#intref0200}Rabbit-Anti-mouse Rictor (H-11)Santa Cruz Bisc-271081; RRID: [AB_10611167](nif-antibody:AB_10611167){#intref0205}tetramethyl rhodamine B isothiocyanate-phalloidinSIGMAP1951; RRID: [AB_2315148](nif-antibody:AB_2315148){#intref0210}Alexa Fluor 555 goat anti-mouse IgBiolegend405324; RRID: [AB_2563179](nif-antibody:AB_2563179){#intref0215}FITC Donkey anti-rabbit IgGBiolegend406403; RRID: [AB_893531](nif-antibody:AB_893531){#intref0220}Hexokinase 1Abcamab65069; RRID: [AB_1140844](nif-antibody:AB_1140844){#intref0225}HK2Abcamab76959; RRID: [AB_2248229](nif-antibody:AB_2248229){#intref0230}Mouse anti-Human CD3-Alexa Fluor 700eBioscience56-0038-80; RRID: [AB_906222](nif-antibody:AB_906222){#intref0235}Mouse anti-Human CD4-APCBD Biosciences555349Mouse anti-Human CD25-PerCP Cyanine 5.5eBioscience45-0259-41; RRID: [AB_10717820](nif-antibody:AB_10717820){#intref0240}Mouse anti-Human CD127-PEeBioscience12-1278-42; RRID: [AB_10717663](nif-antibody:AB_10717663){#intref0245}Mouse anti-Human CD152 (CTLA-4)-BV786BD Biosciences563931Mouse IgG2a, κ Isotype Control-BV786BD Biosciences563732Mouse anti-Human CD357(AITR/GITR)-PE-eFluor 610eBioscience61-5875-41; RRID: [AB_2574625](nif-antibody:AB_2574625){#intref0250}Mouse IgG1 K Isotype Control PE-eFluor 610eBioscience61-4714-80; RRID: [AB_2637443](nif-antibody:AB_2637443){#intref0255}Mouse anti-Human CD69-PECy7eBioscience25-0699-41; RRID: [AB_1548723](nif-antibody:AB_1548723){#intref0260}Mouse anti-Human CD45RA-FITCBD Biosciences555488; RRID: [AB_395879](nif-antibody:AB_395879){#intref0265}Mouse anti-Human CD197 (CCR7)-PEBD Biosciences552176; RRID: [AB_394354](nif-antibody:AB_394354){#intref0270}Mouse anti-Human Ki67-eFluor 450eBioscience48-5699-41; RRID: [AB_10804032](nif-antibody:AB_10804032){#intref0275}Mouse anti-Human FoxP3-APCeBioscience17-4777-41; RRID: [AB_2573208](nif-antibody:AB_2573208){#intref0280}**Chemicals, Peptides, and Recombinant Proteins**ProLong Gold AntifadeLifeTechnologiesP36930Type IV CollagenaseSigma,Cat\# C5138trypsin/ (EDTA)GIBCOCat\# E7889DMEMGIBCO,Cat\# 11966-02510% FBSSeralab,Cat\# A210009Dulbecco'sModified Eagle media (DMEM)GIBCOCat\# 41966-052glutamineGIBCOCat\# 250-302-Mercaptoethanol (2-ME)GIBCOCat\# 31350-010sodium pyruvateGIBCO,Cat\# 11360-039HEPESGIBCOCat\# 15630-056non-essential amino acidsGIBCO,Cat\# 11140-050trypsin/EDTAGIBCOCat\# T4049murine IFN-γPeproTechCat\# 315-05Red blood cell lysis bufferSigma-Aldrich,Cat\# R7757RPMI 1640 mediumGIBCOCat\# 21875-034GMCSF hybridomaDr. Jian-Guo ChaiNAMurine TNF alphaPeprotechCat\# 315-01AZymosanSigma-AldrichCat\# z4250mitomycin CSigma-AldrichCat\# M4287Recombinant human IL-2RocheCat\# 10799068001Recombinant murine CCL22PeprotechCat \# 250-23succinimidyl ester dyes CFSEInvitrogenCat\# C1157PKH26Sigma-AldrichCat\# PKH26GL-1KTDDAO-SEInvitrogenCat\# C34553OCTThermo Fisher ScientificCat\# 12678646glucose free T cell mediumGIBCOCat\# 11879-0206-NBDGLife Technologies,Cat\# N23106RNeasy Mini Kit (50)QIAGENCat No./ID: 74104iQ SYBR Green SupermixBiorad\#1708880High-Capacity RNA-to-cDNA KitLife Technologies,4387406TaqMan human L 750 uL 80X -- assay ID: C\_\_\_2862880_1\_Applied Biosystem4351374TaqMan MasterMix 50 MLApplied Biosystem43713574--20% Mini-PROTEAN TGX Precast Protein GelsBiorad\#4561096Recombinant Mouse ICAM-1-Fc ChimeraBiolegend553004Recombinant human MIP-3β (CCL19)Peprotech300-29BRecombinant human Exodus-2 (CCL21)Peprotech300-35Recombinat human IL-2Peprotech200-02Anti-Human CD3 PurifiedeBioscience14-0039-82Anti-Human CD28 PurifiedeBioscience14-0289-821-step Fix/lyse solutioneBioscience00-5333-54UltraComp eBeadseBioscience01-2222-42Ficoll-Plaque PREMIUMGE-Healthcare17-5442-03**Critical Commercial Assays**Dynabeads FlowComp Mouse CD4^+^CD25^+^ Treg Cells KitInvitrogenCat\#11463DXF assay mediumAgilent TechnologiesCat\# 102365-100Seahorse XF Cell Mito Stress Test KitAgilent Technologies103015-100Seahorse XF Glycolysis Stress Test KitAgilent Technologies103020-100Anti-Mouse/Rat Foxp3 Staining Set APCeBioscience77-5775-40Foxp3 / Transcription Factor Staining Buffer SeteBioscience00-5523-00FlexiGene DNA kitQIAGEN51206CD4^+^CD25^+^ Regulatory Tcell isolation kit, humanMiltenyi Biotec.130-09-301**Experimental Models: Cell Lines**Primary microvascular endothelial cellsNA([@bib25])Bone marrow-derived dendritic cellsThis paperNACD4^+^CD25^+^ Treg cellsThis paperNAHEK293TATCCCRL-11268CD4^+^ effector T primary cellsThis paperNA**Experimental Models: Organisms/Strains**C57BL/6 miceThe Jackson laboratory000664CBA/Ca miceThe Jackson laboratory000654BALB/c miceThe Jackson laboratory000651*Foxp3-GFP* (Foxp3-IRES-EGFP) genetically targeted miceDr B MalissenNA*Cd28*^*Y170F*^Dr Klaus Okkenhaug([@bib36])**Oligonucleotides**Glucokinase (hexokinase 4) primer: F:CAACTGGACCAAGGGCTTCAA; R:TGTGGCCACCGTGTCATTCthis paperNAGlut1: F:CACTGTGGTGTCGCTGTTTG; R:ATGGAATAGGACCAGGGCCTthis paperNAHexokinase I: F:ATGATCGCCGCGCAACTAC; R:AGAGCCGCATGGCATACAGAthis paperNAHexokinase II: F:CCGTGGACTGGACAACCTCA; R:CGTCACATTTCGGAGCCAGAthis paperNARictor: F:TCCCTCTAAGTTCTCGGGGA; R:TTAATGGTCAGAAGCCCGGTthis paperNAGlucokinase Regulator: F:CAGCGTGAGTTAAGCACCAA; R:TCAGTGATGGAGCACCTGAGthis paperNASerpinb9: F:CAGAGTTGTTGTCAGGTGGC; R:CGACACATCATCTGCACTGGthis paperNAGAPDH: F:AGAACGGGAAGCTTGTCATCA; R:GACCTTGCCCACAGCCTTGthis paperNACCR4: F:TGGTGGAGCTTGAAGTCCTT; R:GGACATGTCAGCCGAGTAGAthis paperNACCR7: F:GGGCTGGTGATACTGACGTA; R:ACACAGGTAGACGCCAAAGAthis paperNACD103: F:GGGTCCTACTTTGGCTCTGT; R:GTGTGTGTGCCAAGGAGAAGthis paperNACD62L: F:GGGAACGAGACTCTGGGAAA; R:ACCACATACTGACACTGGGGthis paperNACD69: F:AAGGACCATGGCACCAGTAT; R:AGGTAGCAACATGGTGGTCAthis paperNACXCR3: F:GGGGTCTCTGTCTGCTCTTT; R:CCTCATAGCTCGAAAACGCCthis paperNACD11a: F:TCCGGAAAGTGGAGATGC T; R:GAAGTCTTCCCAGGAGCTGTthis paperNACD49d: F:AGCCGTTGGTGCATTTCAAT; R:TGTAGCCTGGGACCTCTTTGthis paperNA**Recombinant DNA**pLKO.1 target gene set GckSigmaTRCN0000012401pLKO.1 target gene set RaptorSigmaTRCN0000077472pLKO.1 -- scramble shRNAAddgenePlasmid \#1864pLKO.1 target gene set RictorSigmaTRCN0000123394pMD2.GAddgenePlasmid \#12259pRSV-RevAddgenePlasmid \#12253pMDLg/pRREAddgenePlasmid \#12251**Software and Algorithms**Graphpad prismGraphpad<http://www.graphpad.com>SPSS version 21IBM Corporation<https://www.ibm.com/software/it/analytics/spss/>Flow Jo_v10FlowJo<http://www.flowjo.com/>Microscopy Imaging softwareAxioVision Rel.4.8<http://www.zeiss.com>ImageJImageJ<https://imagej.nih.gov>Confocal microscopyLeica LAS softwareNAAdobe PhothoshopAdobe systemsNANovoExpressAcea Bioscience, Inc.https://aceabio.com/products/novocyte/
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Further information and requests for reagents may be directed to, and will be fulfilled by the corresponding author Federica Marelli-Berg (<f.marelli-berg@qmul.ac.uk>).

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Ethical statement {#sec5.3.1}

Human blood was obtained from healthy donors according to ethical approval from the Università degli Studi di Milano (Cholesterol and Health: Education, Control and Knowledge -- Studio CHECK \[SEFAP/Pr.0003\] -- reference number Fa-04-Feb-01). All *in vivo* experiments were conducted with strict adherence to the Home Office guidelines (PPL 70/7443) following approval by the Queen Mary University of London Ethics committee.

### Mice {#sec5.3.2}

All mice used in the experiments of this study were 7-11 weeks. C57BL/6, BALB/c and CBA/Ca mice were purchased from Charles River (UK). The *Foxp3-GFP* (Foxp3-IRES-EGFP) genetically targeted mice on the C57BL/6 background were kindly provided by Dr B Malissen (Centre d'Immunologie de Marseille-Luminy, Marseille, France). The *Cd28*^*Y170F*^ genetically targeted mice on the C57BL/6 background were provided by Dr K Okkenhaug (Babraham Institute). Excised secondary lymphoid organs from 4 week-old *Ctla-4*^*−/−*^ mice (of H-2u haplotype) were provided by Prof D Wraith (University of Birmingham).

### Isolation of microvascular endothelial cells {#sec5.3.3}

Murine lung microvascular endothelial cells were isolated as previously described ([@bib25]). Mouse lungs were diced into 2-3mm^3^ blocks, washed in phosphate buffered saline (PBS; Sigma-Aldrich, Cat\# D8537) and digested in a solution containing 0.5mg/ml Type IV Collagenase (Sigma, Cat\# C5138) for 30 minutes in a humidified incubator maintained at 37°C. A 70μm cell strainer (Fisher scientific, Cat\# 22363548) was then used to remove undigested tissue while the digested tissue was collected and centrifuged at low rpm (\< 250 g). The supernatant was aspirated and further digested in trypsin/ (EDTA) (GIBCO, Cat\# E7889) at 37°C for 5 minutes to create a uniform cell suspension. The cell suspension was then washed with PBS at 300 g and resuspended in DMEM (GIBCO, Cat\# 11966-025) containing 10% FBS (Seralab, Cat\# A210009). The cells were then seeded in 2% gelatinated (Sigma-Aldrich, Cat\# 1393) 25 cm^2^ culture flasks (Helena biosciences, Cat\# 90026) for 24 hours. After 24 hours, non-adherent cells were removed by washing with warm PBS and complete EC medium (mentioned below) was added to the culture.

### EC culture {#sec5.3.4}

EC medium consisted of Dulbecco's Modified Eagle media (DMEM, GIBCO, Cat\# 41966-052) supplemented with 2 mM glutamine (GIBCO, Cat\# 250-30), 50 IU/mL penicillin (GIBCO, Cat\# 15140-122), 50 μg/mL streptomycin (GIBCO, Cat\# 15140-122), 50 μM 2-Mercaptoethanol (2-ME) (GIBCO, Cat\# 31350-010), 1mM sodium pyruvate (GIBCO, Cat\# 11360-039), 20mM N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid (HEPES) (GIBCO, Cat\# 15630-056), 1% non-essential amino acids (GIBCO, Cat\# 11140-050), 20% FCS and 150 μg/ml EC growth supplement (Sigma-Aldrich, Cat\# E0760). Medium was replaced every 48 hours. When confluent, cells were detached with trypsin/EDTA (GIBCO, Cat\# T4049) and passaged.

For functional assays, ECs were used between passages 2 and 8 and treated with 600 U/mL murine IFN-γ (PeproTech, Cat\# 315-05) for 48 to 72 hours prior to use in experiments.

### Isolation of bone marrow-derived Dendritic Cells (BMDCs) {#sec5.3.5}

Bone marrow(BM)-derived DCs were obtained from WT BALB/c (H2-d) mice. Femurs and tibias from 7--to-10-week-old female mice were removed and BM cells were flushed out with PBS using a 27-gauge needle (Becton Dickinson, Cat\# 302200). Red blood cells were lysed from the cell suspension with lysis buffer (Sigma-Aldrich, Cat\# R7757). BM cells (5x10^6^) were seeded per well in a 6 well plate (Helena bioscience, Cat\# 92006) in DC medium as described below.

### Culture of Dendritic cells {#sec5.3.6}

Bone marrow-derived dendritic cells were cultured in RPMI 1640 medium (GIBCO, Cat\# 21875-034) supplemented with 10% FCS, 2mM glutamine, 50 IU/mL penicillin, 50 μg/mL streptomycin, 50 μM 2-ME and 2% murine granulocyte-macrophage colony stimulating factor (GM-CSF) obtained from the supernatant of the GMCSF hybridoma (gift from Dr. Jian-Guo Chai, Imperial College, London, UK). Cells were cultured at 37°C in the presence of 5% CO~2~. On days 3 and 5, fresh culture medium was added to the plates.

For Treg-DC cell co-cultures, immature BMDCs were collected and used on day 6 of culture. For functional assays, immature DCs were matured overnight with 100ng/ml lipopolysaccharide (LPS) (Invivogen, Cat\# tlrl-3pelps) and were used between day 7-10 post-isolation.

### Culture of H2-d allospecific Treg cells {#sec5.3.7}

CD4^+^CD25^+^ Treg cells were isolated from spleen and lymph nodes using Dynabeads® FlowComp Mouse CD4^+^CD25^+^ Treg Cells Kit (Invitrogen Dynal, Cat\#11463D). For extremely high purity of Treg cells (\> 99%), CD4^+^CD25^+^Foxp3^+^ cells were obtained from Foxp3-GFP reporter mice through Fluorescence-activated Cell Sorting. For expansion, Treg cells isolated from C57BL/6 (H2-b) mice were stimulated weekly with either irradiated or mytomycin C (Sigma-Aldrich, Cat\# M4287)-inactivated immature BALB/c-derived (H2-d) DCs at a ratio of 5:1 (Treg:DC) ([@bib13]). The co-cultures were maintained in complete T cell medium supplemented with 10U/ml IL-2. Cells were harvested and seeded at an optimal density of 1.5x10^6^ Treg cells per well of a 24-well tissue culture (Helena bioscience, Cat\# 92024) plate each week. The percentage of CD4^+^Foxp3^+^ cells after two weeks of culture was greater than 95%. For use in functional assays, Treg cells were used 6-8 days after stimulation.

### Antibody-mediated T cell activation {#sec5.3.8}

Activated T cells were obtained by polyclonal stimulation of LN cells with plate-bound anti-CD3 (1 μg/ml, eBiosciences, Cat\# 16-0032-85) and plate-bound anti-CD28 (5 μg/ml, eBiosciences, Cat\# 16-0281-86) in complete T cell medium supplemented with 20 U/ml recombinant IL-2 (Roche, West Sussex, UK) for 7 days at 37°C. Antibody coating of tissue culture plates was performed by incubating antibodies in 200 μL of Tris buffer (pH 8.5) at 37°C for 1 hour.

Method Details {#sec5.4}
--------------

### Lymphocyte trans-endothelial migration and chemotaxis assays {#sec5.4.1}

Primary microvascular ECs treated with IFN-γ for 48--72 h were seeded (3x10^4^) and cultured on 2% gelatin-coated Transwell inserts (diameter, 6.5 mm) containing 3-μm pore size (Costar, Cat\# CLS3472-48EA) polycarbonate membranes in EC medium for 16 h to from a monolayer. T cells (5x10^5^) resuspended in migration medium (RPMI 1640 supplemented with 2% fetal bovine serum) were added to each insert and left to migrate through the monolayer; the well volume was also replaced with fresh migration media. The number of migrated T cells was determined by a hemocytometer counting of the cells present in the well media at different time points over a 24-h period. To measure chemotaxis, T cells were seeded onto Transwell bare-filter tissue culture well inserts (diameter, 6.5 mm) with 5- or 3-μm pore size (Costar, Cat\# CLS3421-48EA) polycarbonate membranes and chemokine-containing migration medium was placed in the bottom of the well. The number of migrated cells was determined by a hemocytometer.

### Assessment of Treg cell apoptosis {#sec5.4.2}

Apoptosis of Treg cells treated with increasing doses of TNFα (5 and 50 ng/ml, PeproTech,INC, Cat\# 315-01A) or heat was measured using Annexin V-FITC Apoptosis Detection Kit (Abcam, Cat\#ab14085). Cells were subsequently analyzed using flow cytometry.

### Induction of CD28, CTLA-4 and LFA-1 signaling {#sec5.4.3}

Induction of CD28 and CTLA-4 signaling by antibody stimulation was performed as previously described ([@bib40], [@bib48]). To induce co-stimulatory signals via CD28 and CTLA-4 co-receptors for functional assay, cells were incubated with antibodies targeting the functional domains of the co-receptors. To induce CD28 signaling, T cells were treated with a mixture of hamster anti-mouse CD28 (5 μg/5x10^6^ cells) (clone: 37.52, Bio-Rad, Cat\# MCA1363) and goat anti-hamster immunoglobulin (Ig) (2.5 μg/5x10^6^ cells) (Bio-Rad, Cat\# STAR104) for different time points as described in each figure separately. Similarly, CTLA-4 signaling was achieved by incubating T cells with a mixture of hamster anti-mouse CTLA-4 (5 μg/5x10^6^ cells) (clone: UC10-4F10-11, Becton Dickinson, Cat\# 553718), and goat anti-hamster immunoglobulin (Ig) (2.5 μg/5x10^6^ cells) (Bio-Rad, Cat\# STAR104). A hamster IgG isotype control was used to observe any non-specific effects of the antibody stimulation (Bio-Rad, Cat\# MCA2356). To induce LFA-1 signaling, cells were incubated with 2 μg/5x10^6^ cells recombinant mouse ICAM-1-human IgG Fc chimeras (2 μg/ml, R&D Systems, Cat\# 796-IC-050) or human IgG-Fc fragments (R&D Systems, Cat\# 110-HG) as a control -- either plastic-bound or ligated with a mouse anti-human IgG (1 μg/ml, MK1A6, Bio-Rad Cat\# MCA647G) - for different time points as described in each figure separately. T cells were washed in PBS prior to use in the experiments.

### Fluorescent labeling of viable T cells {#sec5.4.4}

For labeling T cells with fluorescent probes, T cells were washed with PBS, counted and resuspended in PBS at a final concentration of 10^7^/ml. If necessary, dead cells were removed using density gradient centrifugation with Ficoll-Paque prior to re-suspension. Labeling of T cells with PKH26 (Sigma-Aldrich, Cat\# PKH26GL-1KT), a cell linker dye for cell membranes was performed using manufacturer instructions. PKH26 was added at a final concentration of 5μΜ, and the cells were incubated at room temperature for 5 minutes. The reaction was inactivated by adding an equal volume of FBS to the cell suspension and the cells were washed in PBS containing 10% FBS for 10 minutes. Labeling of T cells with succinimidyl ester dyes CFSE (Invitrogen, Cat\# C1157) or DDAO-SE (Invitrogen, Cat\# C34553) was performed by incubating the T cells in PBS containing final concentration of 3.3 μM CFSE or 1.3 μM DDAO-SE for 10-15 minutes at room temperature. The reaction was terminated by adding equal volume FBS and the cells were then washed with PBS containing 10% FBS for 10 minutes.

### T cell recruitment in the peritoneum {#sec5.4.5}

To observe *in vivo* recruitment of T cells we used a previously described model ([@bib29]). Either PKH26 or CFSE or DDAO-SE-labeled T cells (10^7^) were injected intravenously (i.v.) into mice that hd received IFN-γ (600U) via intraperitoneal injection (i.p.) 48 to 72 hours earlier. Labeled T cells recovered via peritoneal lavage were analyzed 16 hours later using flow cytometry. In addition, localization of Treg cells to the spleen, where entry occurs in a passive manner, was analyzed to ensure that similar numbers/proportion of labeled cells were injected or co-injected in all recipients (internal control).

### Zymosan-induced peritonitis {#sec5.4.6}

On day 0, mice were given intraperitoneal injections of Zymosan (1 mg/mouse, Cat\# 4250 SIGMA) in sterile saline solution to induce peritonitis. Mice were sacrificed 72 hours post-injection and tissue samples obtained for flow cytometry analysis.

### Widefield deconvolution fluorescence microscopy {#sec5.4.7}

Tissues samples were excised, embedded in Optimal Cutting Temperature compound (OCT; Thermo Fisher Scientific, Cat\# 12678646), snap-frozen and stored until analysis. Frozen tissue sections were laid onto Polysine coated microscope slides (VWR International, Cat\# 47100), air-dried and then fixed with ice cold acetone (Sigma, Cat\# 534064) for 10 min. Tissue sections were washed in PBS, blocked with serum for 3 hours and stained using mentioned primary antibodies at 4°C for 24 h. Excess antibody was washed away with PBS and tissues were stained with indicated secondary antibodies along with DAPI (4',6-diamidino-2-phenylindole) (Invitrogen/LifeTechnologies, Cat\# D1306) for 30 min at room temperature. Slides were washed, mounted in ProLong Gold Antifade Reagent (Invitrogen/Life Technologies, Cat\# P36930) and visualized using a Zeiss Z1 fluorescence microscope (Carl Zeiss, UK) equipped with an AxioCam MRm Cooled monochrome digital camera and an Apotome 2 Imaging unit. Images were acquired using a Plan Apochromat 20x/0.8 NA objective and Axiovision software version 4.8 (Carl Zeiss, UK). For staining, Treg cells were cultured in R10 medium and fixed with 3.7% formaldehyde. After fixing, they were stained with anti- GCK, anti-Na,K-ATPase and 1 ng/ml tetramethyl rhodamine B isothiocyanate--conjugated phalloidin (Sigma-Aldrich Cat\# P1951) for 30 min at 37°C and respectively. This was followed by secondary antibodies Alexa Fluor® 555 goat anti-mouse Ig (Biolegend Cat\# 405324) and FITC Donkey anti-rabbit IgG (minimal x-reactivity) Antibody (Biolegend 406403). Coverslips were extensively washed, air-dried, and mounted in Vectorshield mounting medium for fluorescence with DAPI (Vector Laboratories Cat\# z0603) on glass slides.

### Confocal microscopy {#sec5.4.8}

Cells were allowed to adhere onto poly-L-lysine coated coverslips and fixed in 4% paraformaldehyde (Thermo Fisher Scientific, Cat\# 28906) for 5-10 minutes at room temperature. Where mentioned, permeabilization was carried out using 0.2% Triton X-100 (Sigma-Aldrich, Cat\# X100-500ML) in PBS for 5 minutes. Cells were then washed in PBS, blocked in blocking buffer (PBS containing 0.1% Fish skin gelatin; Sigma-Aldrich, Cat\# G7765) and 1% serum of the species giving rise to secondary antibodies) for 3-6 hours and then stained with appropriate primary antibodies at 4°C for 16 hours in the dark. Following staining, cells were washed again and stained with corresponding secondary antibodies and DAPI for 30 minutes at room temperature. After multiple PBS washes coverslips were mounted onto slides using ProLong Gold Antifade (Invitrogen/Life Technologies, Cat\# P36930) and then examined using a Leica SP5 confocal microscope equipped with a 63 × 1.4 NA objective. Confocal images and Z stacks were acquired and analyzed by Leica LAS software. Repositioning of scale bars and image layouts were prepared using Adobe Photoshop (Adobe Systems). All images in a group were treated equally.

### *In vitro* 6-NBDG uptake assay {#sec5.4.9}

Freshly isolated or cultured T cells were washed in PBS and resuspended in glucose free T cell medium (GIBCO, Cat\# 11879-020) containing various mentioned signaling antibodies and incubated for 45 minutes at 37°C with 5% CO2. A final concentration of 400 μM 6-NBDG (Life Technologies, Cat\# N23106) in glucose free T cell medium was then added to the cells and the cells were further incubated for an additional 10-15 minutes. Finally, the cells were washed twice with warm PBS and resuspended in flow cytometry buffer and placed on ice. Immediate analysis was performed using flow cytometry to observe fluorescence uptake by the T cells.

### *In vitro* 6-NBDG uptake assay (human studies) {#sec5.4.10}

Freshly isolated CD3^+^ T cells were washed in PBS and cultured 10^6^/mL in R2 (RPMI 1640 supplemented with 2% fetal bovine serum) with recombinant CCL19 and CCL21 (200 ng/mL - Peprotech Cat\#300-29B and 300-35) at 37°C with 5% CO~2~. A final concentration of 400 μM 6-NBDG (Life Technologies, Cat\# N23106) was added to the cells and incubated for 0, 15, 30 and 60 minutes. Finally, the cells were washed twice with warm PBS, stained for CD4^+^ T cells and Treg and placed on ice. Immediate analysis was performed using flow cytometry to observe fluorescence uptake by Treg cells.

### *In vivo* 6-NBDG uptake assay {#sec5.4.11}

To measure glucose uptake activity of T cells *in vivo*, PKH26 labeled T cells (3x10^6^) were injected i.p. into mice. A second i.p. injection of 6NBDG (400 μM in Sterile water) was given to the mice immediately afterward. After a 1-hour period, the mice were sacrificed and the mesenteric (draining) lymph nodes and spleen collected for analysis by flow cytometry. Widefield microscopy of the peritoneal membranes was performed to observe influx of labeled T cells into the peritoneal membrane. PKH26^+^ T cells infiltrating the membranes were further analyzed for 6NBDG uptake (green fluorescence) using image analysis software ImageJ. The number of labeled cells in 10x magnification field views images was counted manually to determine differences in T cell infiltration.

### Measurement of ECAR and OCR {#sec5.4.12}

Real time bioenergetics analysis of extracellular acidification rates (ECAR) and oxygen consumption rates (OCR) of T cells subjected to antibody stimulation was performed using the XF analyzer (Seahorse biosciences). T cells were cultured in serum free, unbuffered XF assay medium (Seahorse biosciences, Cat\# 102365-100) for 1 hour. The cells were then seeded (6x10^5^/well) into the seahorse XF24 cell plates for analysis. Perturbation profiling of the use of metabolic pathways by T cells was achieved by the addition of oligomycin (1 μM), FCCP (1 μM), Antimycin A (1 μM), rotenone (1 μM), D-glucose (10mM), 2-Deoxy-D-glucose (2DG, 50mM; all from Seahorse biosciences, Cat\# 103020-100 and 103015-100). Experiments with the Seahorse system were done with the following assay conditions: 2 min mixture; 2 minutes wait; and 4--5 min measurement. Metabolic parameters were calculated. Experiments were done in at least triplicate wells.

### Surface staining {#sec5.4.13}

For surface staining, cells were resuspended (10^7^/ml) and stained with flurochrome- conjugated antibodies in 100 μL of Flow cytometry buffer made of PBS containing 0.1% sodium azide (Sigma-Aldrich, Cat\# S2002-25G) and 1% FBS at 4°C for 30 minutes. CCR7 antibody staining was performed at 37°C for 30 mins. Optimal antibody concentrations for staining were calculated based on manufacturer instructions. Following staining, cells were washed and resuspended with flow cytometry buffer and analyzed immediately. Alternatively, for delayed analysis, cells were fixed in fixation buffer (flow cytometry buffer containing 1% Formaldehyde, Sigma-Aldrich, Cat\# 15,812-7)) for 30 minutes at 4°C, washed and stored in flow cytometry buffer at 4°C. The table below indicates the fluorescent antibodies that were used in this study.

### Intracellular staining {#sec5.4.14}

For intracellular Foxp3 staining, eBioscience Anti-Mouse/Rat Foxp3 Staining Set APC (clone FJK-16S, Thermo Fisher Scientific Cat\# 17-5773-82) kit was used. Cells were resuspended (10^7^/ml) and stained with surface antigens as mentioned above and then fixed/permeabilized for 30 minutes at 4°C using Fixation/Permeabilization working solution made from mixing 1 part of the fixation/permebilization concentrate (eBioscience, Cat\# 00-5123) to 3 parts of the fixation/permebilization diluent (eBioscience, Cat\# 00-5223). The cells were then washed twice in 1X permeabilization buffer (eBioscience, Cat\# 00-8333) and stained with fluorochrome conjugated-Foxp3 antibody in 1x permeabilization buffer for 30 minutes at 4°C. A final wash with 1x permeabilization buffer was performed and the cells were then centrifuged and resuspended in 200ul of flow cytometry buffer. For T cell proliferation studies, Treg cells were stimulated with immature BALB/c DCs. 3 hours later, Treg cells were fixed and permeabilized with ice cold 70% ethanol before staining for proliferating cell nuclear antigen (PCNA, clone PC10, BioLegend Cat\# 307908).

### *In vitro* AKT phosphorylation (human studies) {#sec5.4.15}

Freshly isolated concentional CD4^+^CD25^-^ T cells (Tconv) and CD4^+^CD25^+^ (Treg) T cells were washed in PBS and cultured 5 × 10^6^/mL in R2 (RPMI 1640 supplemented with 2% fetal bovine serum). 0.5 × 10^6^ CD4^+^CD25^-^ (Tconv) and CD4^+^CD25^+^ (Treg) were plated in 96-well plate and stimulated for 15 minutes or not with chemokines CCL19 and CCL21 (1 μg/mL - Peprotech Cat\# 300-29B and 300-35) at 37°C with 5% CO~2~. Cells were immediately fixed to stop stimulation with 2% formaldehyde for 10 minutes at RT in the dark. Cells were washed and resuspended in 100% ice-cold methanol and incubated for 30 minutes on ice. Subsequently, cells were washed twice with PBS 2%FBS and stained for pAKT-s473 (eBioscience, Cat\# 17-9715-41) for 30 minutes at 4°C in the dark. Cells were washed, resuspended in PBS 2%FBS and immediately analyzed by flow cytometry.

### Western Blotting and coimmunoprecipitation {#sec5.4.16}

Whole-cell lysates were lysed in Nonidet P-40 lysis buffer \[50 mM HEPES (pH 8.0), 350 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 20 mM glycerol-2-phosphate, 1 mM PMSF, 1 mM DTT, 10 μg/mL aprotinin, 10 μg/mL leupeptin, and protease inhibitor cocktail (Roche Cat\# 11836145001). Equivalent amounts of protein as determined by standard Bradford assay (Bio-Rad Cat\# 5000001) were separated by SDS/PAGE and transferred to nitrocellulose membrane (GE Healthcare Life Sciences Cat\# 10600002). Membranes were blocked for 2 h at room temperature in 5% milk/TBS-Tween 20 (Sigma Cat\# P1379) and were incubated overnight at 4°C with the primary antibodies listed below. HRP-conjugated secondary antibody (1:5000; Amersham Bioscience Cat\# NA934) was subsequently added. Films were then developed. The intensity of the bands was quantified using ImageJ (NIH). For coimmunoprecipitation experiments, cell extracts were prepared in RIPA buffer. 250 μg of total protein extract was first precleared with Protein G--Agarose beads (Sigma Cat\# P3296) for 1 hour at 4°C, incubated with 5 μg of anti-GCK Ab (Santa Cruz Biotechnology Cat\# SC7908) overnight at 4°C and then with Protein G beads for another 16hrs at 4°C. The final pellet was resuspended in 10 mM Tris HCl, pH 7.4, supplemented with 1 mM PMSF and analyzed by western blot for B actin (Santa Cruz Cat\# SC161).

### Quantitative real time PCR (qRT-PCR) {#sec5.4.17}

Tissues were harvested and stored in RNA-later (QIAGEN Cat\# 76104) at --80°C until processing. RNA was purified using Trizol reagent (Life Technologies Cat\# 15596) according to the manufacturer's instructions and assessed for quality and quantity using absorption measurements. Reverse transcription was performed according to the manufacturer's instruction (Applied Biosystems Cat\# 4374966). Gene expression analysis was done using SYBR Green Supermix (Biorad Cat\# 1725120) in CFX connect light cycler (Biorad Cat\# **1855200**). Expression was calculated using the ΔΔCt method ([@bib23]) and normalized to a housekeeping gene (GAPDH). Primers for qPCR were designed with the help of online tools (Primer 3Plus) using at least one exon junction-binding site per primer pair. The thermal cycling profile for amplification was 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 54°C for 1 min. Amplification was at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. To ensure the amplification specificity, the melting curve program was set as follows: 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s, right after the PCR cycles. Experiments were done in triplicates.

### Lentivirus Preparation for Gene Silencing {#sec5.4.18}

HEK293T cells were grown in 10cm cell-culture dishes to 70% confluence and were transfected with the above plasmids using the calcium phosphate method. The supernatant was harvested 48 and 72 h after transfection and was concentrated 100-fold in an ultracentrifuge. Aliquots were stored at −80°C. For transduction of Treg cells, cells were seeded in six-well plates and cultured in DMEM to 60%--70% confluence. Lentivirus was added to the cells in the presence of 5 μg/mL Polybrene (Sigma-Aldrich Cat\# 107689), and the six-well plate was centrifuged at 2,300 rpm for 90 min at room temperature, followed by 8 h incubation at 37°C with 5% CO~2~. Virus was removed 24 h later; T cells were washed twice with PBS and incubated for 24 h in complete DMEM (Life technologies, Cat\# 1852730).

### Study population {#sec5.4.19}

The Progressione della Lesione Intimale Carotidea (PLIC) Study (a sub-study of the CHECK study) is a large survey of the general population of the northern area of Milan (n = 2.606) ([@bib1], [@bib24], [@bib34], [@bib33]), followed at the Center for the Study of Atherosclerosis, Bassini Hospital (Cinisello Balsamo, Milan, Italy). The Study was approved by the Scientific Committee of the Università degli Studi di Milano ("Cholesterol and Health: Education, Control and Knwoledge -- Studio CHECK ((SEFAP/Pr.0003) -- reference number Fa-04-Feb-01) in Febraury 4th 2001. An informed consent was obtained by subjects in accordance with the Declaration of Helsinki.

Genomic DNA was extracted using Flexigene DNA kit (QIAGEN, Milan, Italy). Genotyping for the p.Leu446Pro *GCKR* missense mutation was available on the entire population, using TaqMan allelic discrimination test. The experimental analysis was conducted on a subgroup of 16 subjects, eight Leu 446-*GCKR* and eight Pro 446-*GCKR* matched for age and gender.

### Blood surface and intracellular staining (human studies) {#sec5.4.20}

For surface staining, 100μL of whole blood were stained with flurochrome-conjugated antibodies in 50 μL of MACS buffer made of PBS containing, 2% FBS and 2μM EDTA at RT (room temperature) for 30 minutes in the dark. Optimal antibody concentrations for staining were calculated based on manufacturer instructions. Following staining, red blood cells were lysed with 2 mL of 1-step fix/lyse solution (eBioscience, Cat\#00-5333-54) for 20 minutes at RT, washed and resuspended with MACS buffer and analyzed immediately.

Alternatively, for intracellular staining, peripheral blood mononuclear cell (PBMCs) were isolated (as described below) and used for the staining (1-step fix/lyse solution is incompatible with some intracellular stainings). Cells were resuspended (10^7^/mL) and stained in in 50 μL of MACS buffer with surface antigens. For intracellular Foxp3 and Ki67 staining, eBioscience Anti-Mouse/Rat Foxp3 Staining Kit was used (Cat\#77-5775-40). Cells were fixed/permeabilized ON at 4°C using Fixation/Permeabilization working solution made from mixing 1 part of the fixation/permebilization concentrate to 3 parts of the fixation/permebilization diluent. Cells were then washed twice in 1X permeabilization buffer and stained with fluorochrome conjugated-Foxp3 and --Ki67 antibodies in 1x permeabilization buffer for 30 minutes at 4°C. A final wash with 1x permeabilization buffer was performed and the cells were then centrifuged and resuspended in 200 μL of MACS buffer. The table above indicates the fluorescent antibodies that were used in this study.

### PBMC isolation and CD4^+^CD25^+^ Treg cell purification (human studies) {#sec5.4.21}

For each subject, 30 mL of blood (supplemented with EDTA) were split in two falcon of 15 mL and spin for 12 minutes at 1000xg. Plasma was discarded and the interface between plasma and red blood cells, enriched in leukocytes and platelets (buffy coat), was carefully collected, diluted with cold PBS and stratified on 3 mL of Ficoll-Plaque™ PREMIUM (GE-Healthcare, Cat\#17-5442-03). After centrifugation of 35 minutes at 250xg, PBMC layer was carefully collected and was 3 times with 10 mL of cold PBS at 180xg for 12 minutes to get rid of platelets. PBMC were counted and use for CD4^+^CD25^+^ Treg purification with CD4^+^CD25^+^ Regulatory T cell isolation kit, human (Miltenyi Biotec., Cat\#130-09-301) according to manufacturer instructions. Purified CD4^+^CD25^+^ Treg or CD4^+^CD25^-^ Tconv cell were counted with a hemocytometer and used for migration and suppression assay.

### Treg and Tconv cell migration assay (human studies) {#sec5.4.22}

300 μL of Treg and Tconv cells (1x10^5^) of each subject were resuspended in migration medium (RPMI 1640 supplemented with 2% fetal bovine serum) and cultured on Transwell inserts (diameter, 6.5 mm) with 5-μm pore size (Costar, Cat\# CLS3421-48EA) polycarbonate membranes. Cells were left to migrate versus migration medium or chemokines CCL19 and CCL21 (200 ng/mL - Peprotech Cat\#300-29B and 300-35), placed in the bottom of the well, for 1, 2, 4 and 12 hours. The number of migrated cells was determined by a hemocytometer and data expressed as percentage of migration compared to cultured cells.

### Suppression assay (human studies) {#sec5.4.23}

CD4^+^CD25^-^ Tconv cells were resuspended in MACS buffer (10^7^/mL) and labeled with succinimidyl ester dyes CFSE (2μM - Invitrogen, Cat\# C1157) for 10 minutes at RT in the dark. Cells were washed 3 times with MACS buffer and centrifuged at 360xg for 5 minutes. 96 well-plate U-bottom were coated with anti-human CD3 purified antibody (5 μg/mL - eBioscience, Cat\#14-0039-82) for 1 hour at 37°C. Tconv were resuspended (10^6^/mL) in complete medium (RPMI 1640 supplemented with 10% FBS, 1mM Na-Pyruvate, 10mM HEPES, 50 μM β-MeOH and pen/strep/glutamine) plus 50 U/mL of IL-2 (Peprotech; Cat\#200-02) and 2 μg/mL of anti-human CD28 purified antibody (eBioscience, Cat\#14-0289-82) and (1x10^5^/100 μL) were plated. CD4^+^CD25^+^ Treg cells were washed and resuspended in complete medium and added to Tconv cells according to the following proportions (Tconv:Treg): 1:1, 1:0,5, 1:0,25 and 1:0 by performing serial dilution of Treg cells with complete medium in a 96-well plate. The plate was then spun 1 minute at 120 g and incubated at 37°C for 4 days. Cells were then collected and for each subject the percentage of proliferated cells in the presence of Treg cells was compared to the condition of Tconv:Treg cells 1:0 (100% proliferation).

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

The qPCR data were analyzed using the delta delta CT method by taking the CT values of the genes of interest from the house keeping gene following by normalization to the wild-type control sample. Results were done transported to prism before graphic presentation and statistical analysis.

Results are given as the mean per group ± SD. The data were analyzed using a two-tailed unpaired Student's t test and Mann-Whitney test. A p value of less than 0.05 was considered significant. Experimental datasets from the seahorse were analyzed using one-way ANOVA with Bonferroni correction or Kruskal-Wallis with Dunn's post-test to take into account of multiple comparisons. Where indicated 'n' represent the number of biological replicates. Human data were analyzed by ANCOVA (Analysis of Co-Variances) models between TT and CC genotypes of the rs1260326 GCKR polymorphisms (adjusting by age and gender). In supplemental table variables are presented as mean (standard deviations, SD) if normally distributed or as median (Inter-Quartile Range, IQR) if non normally distributed (Shapiro-Wilk test). t test to compare normally distributed variables and U-Mann Whitney for non-normally distributed variables were performed (p values for each variables are reported; p less than 0.05 are significant). Grubb's test for outliers detection was performed for each variables.

For human results, data are reported as the mean per group ± SEM. The data were analyzed using a two-tailed unpaired Student's t test and Mann-Whitney test. A p value of less than 0.05 was considered significant.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S7Document S2. Article plus Supplemental Information
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